Outcomes after allo-HCT according to disease status at HCT
| Outcomes . | CR (n = 40) . | PR (n = 51) . | Resistant (n = 20) . | P . | |||
|---|---|---|---|---|---|---|---|
| n . | Prob, % (95% CI) . | n . | Prob, % (95% CI) . | n . | Prob, % (95% CI) . | ||
| Adjusted relapse* | 40 | 49 | 19 | ||||
| 1 y | 13 (5-25) | 29 (17-42) | 32 (12-53) | .11 | |||
| 3 y | 16 (6-29) | 31 (18-44) | 47 (22-69) | .05 | |||
| Adjusted NRM | 40 | 49 | 19 | ||||
| 1 y | 18 (5-31) | 23 (12-34) | 33 (14-52) | .47 | |||
| 3 y | 25 (10-41) | 25 (14-36) | 37 (16-58) | .61 | |||
| Adjusted PFS* | 40 | 49 | 19 | ||||
| 1 y | 72 (58-86) | 47 (33-61) | 26 (7-46) | <.0001 | |||
| 3 y | 66 (51-81) | 43 (29-57) | 5 (0-15) | <.0001 | |||
| Adjusted OS | 40 | 51 | 20 | ||||
| 1 y | 80 (67-92) | 67 (54-80) | 45 (23-67) | .02 | |||
| Outcomes . | CR (n = 40) . | PR (n = 51) . | Resistant (n = 20) . | P . | |||
|---|---|---|---|---|---|---|---|
| n . | Prob, % (95% CI) . | n . | Prob, % (95% CI) . | n . | Prob, % (95% CI) . | ||
| Adjusted relapse* | 40 | 49 | 19 | ||||
| 1 y | 13 (5-25) | 29 (17-42) | 32 (12-53) | .11 | |||
| 3 y | 16 (6-29) | 31 (18-44) | 47 (22-69) | .05 | |||
| Adjusted NRM | 40 | 49 | 19 | ||||
| 1 y | 18 (5-31) | 23 (12-34) | 33 (14-52) | .47 | |||
| 3 y | 25 (10-41) | 25 (14-36) | 37 (16-58) | .61 | |||
| Adjusted PFS* | 40 | 49 | 19 | ||||
| 1 y | 72 (58-86) | 47 (33-61) | 26 (7-46) | <.0001 | |||
| 3 y | 66 (51-81) | 43 (29-57) | 5 (0-15) | <.0001 | |||
| Adjusted OS | 40 | 51 | 20 | ||||
| 1 y | 80 (67-92) | 67 (54-80) | 45 (23-67) | .02 | |||
Prob, probability.
Histology at relapse (CLL/SLL vs DLBCL-RS) was not available; therefore, any relapse was considered an event.